Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Takeda scraps late-stage amyloidosis study

Takeda Pharmaceutical Co. Ltd. will discontinue a late-stage study testing the company’s experimental treatment for amyloidosis, which did not meet the first of two main goals.

Read More »

Alzheimer’s: New Approaches and New Hope

Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.

Read More »

Lowering blood pressure cuts risk of memory decline: U.S. study

Aggressively lowering blood pressure significantly reduced the risk of mild cognitive impairment and dementia among hypertension patients in a large government-backed clinical trial, U.S. researchers said.

Read More »

Eli Lilly Ends Another Solanezumab Phase 3 Study

Lilly has closed off another avenue for solanezumab, its once-promising experimental therapy for Alzheimer’s disease, after scrapping another Phase III study.

Read More »

Anavex May Have Just Become a Target for Biogen and Eli Lilly

Anavex Life Sciences Corp. (NASDAQ:AVXL) may have just emerged as a significant player in the Alzheimer’s drug market. The clinical-stage biotech company specializes in the development of treatments for currently incurable diseases. It has stumbled upon AVANEX 3-71 which is a drug candidate that may have significant potential for reduction of synaptic loss, amyloid, and […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom